administration to the elderly volunteers, absolute and normalized glucose metabolic rates were depressed in prefrontal and occipital regions and increased in parietal occipital cortical regions and a left middle temporal region. These changes in the older volunteers are generally not consistent with changes seen in AD. We conclude that deficits in muscarinic system function may contribute to some but not all of the hypometabolic changes seen in AD patients.
fNeuropsychopharmacology 10:191-198, 1994J aspects of the memory impairment that occurs in nor mal aging (Drachman and Leavitt 1974; Molchan et al. 1992 ) and Alzheimer's disease (AD) (Sunderland et al. 1986 ; Molchan et al. 1992 , for review). The pathologi cal changes in the muscarinic cholinergic system of pa tients with AD are thought to contribute to the severe memory impairment that occurs in this disease (Davies and Maloney 1976; Perry et al. 1978 ; Bartus et al. 1982 ; Whitehouse et al. 1982) . Patients with AD have been shown to have decreased cerebral blood flow (CBF) and metabolic rates in the cerebral cortex, with the greatest reductions in parietotemporal regions, and with more frontal involvement later in the disease process (Frack owiak et al. 1981; Foster et al. 1983; Haxby et al. 1988; Friedland et al. 1989 ; Kumar et al. 1991) . It is unknown what neuropathological changes in the brain relate to the decreases in metabolic rate. In this study, using (18F) 2-fluoro-2-deoXY-D-glucose (FOG) in a double in jection paradigm, we sought to explore whether meta bolic rate patterns after acute scopolamine administra tion in older adults were analogous to patterns seen in unmedicated AD patients.
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Many studies have utilized positron emISSIOn tomography (PET) to explore the effects of psychoac tive medications in various patient and normal control groups (Sedvall et al. 1986; Honer et al. 1988; Frey et al. 1992; Gitelman and Prohovnik 1992) . Most prior PET studies though, in looking at effects before and after medication, have done so on different days. This is necessary for examining drugs such as tricyclic an tidepressants, which may take weeks to induce their therapeutic effects. When studying the acute effects of a drug, scanning subjects before and after drug adminis tration in the same session is likely to improve sensi tivity. This is because variability is decreased when the subject does not have to be repositioned in the scanner (Phelps et al. 1984; Bartlett et al. 1988) , when possible state changes across a long span of time are avoided, and when each subject serves as his or her own control (Phelps et al. 1984) . In this study, we used a double in jection paradigm (Brooks et al. 1987; Chang et al. 1987) using (18F) 2-fluoro-2-deoxY-D-glucose (FOG) to ex plore the acute metabolic effects of scopolamine in a group of older normal volunteers.
METHODS
This study was approved by the Internal Review Board of the National Institute of Mental Health and the Radi ation Safety Committee of the National Institutes of Health. Informed consent was obtained from all sub jects.
Subjects
Ten older normal volunteers (Table 1 ) participated in the study after informed consent and screening to ex clude medical and psychiatric illness and family history of dementia or other neuropsychiatric disease. Their evaluation consisted of physical and mental status ex aminations, electrocardiogram, MRI scan of the brain, and laboratory tests for hematologic, hepatic, renal, and thyroid function. They also completed a battery of neu ropsychological tests, which included the Wechsler Memory Scale-Revised (WMS-R) (Wechsler 1987) , to ensure normal memory and other cognitive function. They were paid for their participation and were drug free for at least three weeks prior to the study. 
PET Scan Procedure
Subjects were fasting, and remained supine with eyes and ears uncovered throughout the scans, including the transmission scan, which was used to calculate at tenuation. The scanner (Scanditronix, Essex, MA) has a full-width half-maximum in plane resolution of 5 to 6 mm and a z-axis resolution of 11.8 mm. Blood sam ples from the radial artery were obtained to calculate the tracer input curve. Subjects were free to open and close their eyes; the room was quiet, and no cognitive tasks were done. Each was htted with a plastic hexalite face mask, which was &xed to the scanner headrest. The fIrst FOG injection (3.0 millicuries or 111 MBq) was administered at time 0 through an indwelling in travenous line; this was followed by a 30 minute up take period. Emission scanning then commenced for 30 minutes. After completion of the fIrst emission scan, 0.5 mg of scopolamine hydrobromide was given intra venously over one minute. Thirty minutes later (within the 110 minute half-life of the hrst injection), the sec ond FOG injection (5 millicuries or 185 MBq) was ad ministered. As for the hrst scan, emission scanning fol lowed a 30 minute uptake period ( Figure 1 ). The residual radioactivity from the hrst injection was measured and subtracted from the counts measured during the sec ond scan. The method used for this correction is based on an estimate of k4, which is the dephosphorylation rate of FOG and the rate of decay of 18F (Brooks et al. 1987) .
The dose of scopolamine was chosen based on a prior study of a range of doses which showed that a statistically signifIcant decline in cognitive test perfor mance in older volunteers occurred at the 0.5 mg dose (Sunderland et al. 1986; Molchan et al. 1992) . In the authors' experience, all subjects administered this dose experience cognitive impairment. The timing of the scans was based on prior studies showing that the am nestic effects of IV scopolamine occur to a consistent degree 60 to 150 minutes after administration (Sunder land et al. 1987; Kopelman and Corn 1988; Molchan et al. 1992) .
Twenty-one slices were acquired during each of the two scans, starting at 5 mm above the plane parallel to the canthomeatal (CM) line. The interslice interval was approximately 3.5 mm.
Regions of Interest Analysis
Sixty regions of interest (ROI) were measured in hve standard transaxial planes ( Figure 2 ) (plane A, 94 mm above the CM line; plane B, 81 mm above the CM line; plane C, 67 mm above the CM line; plane 0, 53 mm above the CM line; and plane E, 40 mm above the CM line) by a staff member experienced in the technique and blind to subject identity and drug condition. Since the double FOG procedure eliminates repositioning the head for each scan, the fIve planes selected in the fIrst scan were matched exactly to the same slices or images in the second scan. ROls were primarily from cortical areas, although ROIs which included the thalamus (0 plane), basal ganglia (0 plane), hippocampus (E plane), and cingulate gyrus (B plane) were also sampled. ROIs, which were 7 mm x 7 mm boxes, were placed in a semi-automated procedure through neuroanatom ical matching to a standard PET template based on the brain atlas of Matsui and Hirano (1978) , as has been pre viously described (Clark et al. 1985; Cohen et al. 1988) . Prior studies have shown that the interater reliability of this method of choosing ROIs is very high (r > 0.95) (Semple et a1. 1993) .
Raw pixel values were converted to glucose meta bolic rates in milligrams of glucose per 100 g of tissue per minute (Brooks 1982) . Metabolic rates are expressed as global glucose metabolic rates (estimates of the av erage value for glucose metabolism obtained from all the gray-matter-rich areas of the brain sampled), abso lute regional glucose metabolic rates (average values
Plane Level
Bt--�--r for glucose metabolism obtained from the region of in terest), and normalized regional glucose metabolic rates (regional absolute metabolism rate/global metabolism rate). The normalization procedure was used to mini mize the effects of individual variation in global metab olism on regional metabolism (Bartlett et a1. 1988 ).
Statistics
Comparisons of global and regional metabolic rates be tween off-and on-drug scans were done using both ab solute and normalized values. The analyses were per formed using paired t-tests (two-tailed). In view of the exploratory purpose of the study and the small num ber of subjects, we chose to decrease the probability of Type II errors by omitting corrections for multiple com parisons. Although our hypotheses about metabolic changes after scopolamine could be limited to brain regions reported in previous PET studies, we felt that it would be more appropriate in our initial study in older adults to take advantage of the ability of PET to image large areas of the brain simultaneously. 
RESULTS

Global and Absolute Regional Cerebral Glucose Metabolism
Data are summarized in Figure 3 . There was no significant change in global metabolic rate after scopola mine (7.41 ± 0.58 off-drug vs. 7.39 ± 0.95 mg glu cose/100 g tissue/min on-drug). In six of the 60 ROIs a significant change in absolute regional glucose me tabolism was detected. Decreased regional glucose metabolic rates were detected in three ROIs, two in prefrontal areas and one in occipital cortex. Increased metabolic rates occurred in left and right parietoccipi tal ROIs and a left middle temporal lobe ROI.
Normalized Regional Cerebral Glucose Metabolism
Data are summarized in Figure 4 . Changes were simi lar to the absolute data, with the exception of one of the prefrontal ROIs in which the change did not reach statistical significance.
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Side Effects of Scopolamine
All subjects reported experiencing dry mouth after scopolamine administration. Six subjects experienced motor restlessness, manifested by leg movements; eight subjects were drowsy, and one was lightheaded. Side effects usually began within 15 minutes of injection and lasted throughout the procedure.
DISCUSSION
Using a double FOG/PET paradigm, we found that scopolamine significantly altered regional cerebral glu cose metabolism in a number of brain areas in normal older volunteers. The decreased metabolic rates we ob served in prefrontal cortex may relate to the inatten tiveness and decreased ability to suppress inappropri ate responses typical of AD (Fuld et al. 1982 ) and reported in normal subjects following scopolamine ad ministration (Drachm an and Leavitt 1974; Dunne and Hartley 1985; Broks et al. 1988 ). The decrease in meta bolic rate after scopolamine in an area of the occipital cortex that includes primary visual cortex is consistent
Absolute Metabolic Values
Left and Medial Right with fIndings of others and with the presence of a fairly high concentration of muscarinic receptors in that re gion (Frey et al. 1992; Cohen et al. submitted) . It is also consistent with scopolamine'S effects on the visual evoked potential (Smith et al. 1990 ). challenge with scopolamine may not produce a detect able change.
The most consistent abnormalities found with PET in AD patients are decreased metabolic rates in associ ation cortices, especially parietotemporal (Frackowiak et al. 1981; Foster et al. 1984; Duara et al. 1986; Haxby et al. 1988) , with frontal decreases more evident as the illness progresses (Frackowiak et al. 1981; Haxby et al. 1988; Friedland et al. 1989) . Signiftcant decreases in re gional glucose metabolic rate in occipital cortex have also been reported (Foster et al. 1984; Friedland et al. 1989) . Whether the blood flow/metabolic changes de tected by PET are related to the muscarinic system deficit in AD patients is unknown. The decreased meta bolic rates after scopolamine we found in prefrontal and occipital cortices are consistent with metabolic changes seen in AD brain, but the increased rates in parietoc cipital and temporal lobe ROIs are not.
Three prior neuroimaging studies have examined the effects of scopolamine in humans. The first report used the 133Xe inhalation technique in 15 young nor mal volunteers and found that global CBF, predomi nantly frontal lobe regional CBF, was reduced after scopolamine administration (Honer et al. 1988) . Using the same technique in seven elderly normal volunteers, Gitelman and Prohovnik (1992) found that after com bined administration of scopolamine and the nicotinic antagonist mecamylamine, CBF was similarly reduced in frontal cortex. They also reported a decrease in parietotemporal cortex, similar to that found in AD, in dicating that the combination of these two drugs repli cated the CBF alterations reported in AD better than scopolamine alone. These fIndings are consistent with the known muscarinic (Bartus et al., 1982; Whitehouse et al., 1982) and nicotinic (Whitehouse et al., 1988) defIcits in the illness. In another study, a group of young normal volunteers who had not received scopolamine were compared with a group who received 0.5 mg IV in a FOG/PET study. Decreased metabolic rates were noted in the thalamus, occipital, right frontoparietal, and cingulate cortices; increased metabolic rates were noted in the basal ganglia (Cohen et al. submitted) . This study differed from the current one in a number of ways. Most notably, young normal volunteers were studied, and subjects performed a continuous perfor mance task during the scans. Alterations in the choliner gic system have been reported to occur with age that may alter the response to scopolamine in aged subjects (Molchan et al. 1992 Cortes et al. 1987) .
In summary, the alterations in regional glucose metabolic rates that we found in older volunteers using a double injection method of FDG administration with PET are consistent with some, but not all of the changes found in the brains of patients with AD. This may be due to the involvement in the disease of neurotrans mitter systems besides the muscarinic cholinergic, which scopolamine targets, or to involvement of other pathological lesions such as amyloid plaques in areas of decreased metabolic rates (Honer et al. 1988) . Also, fIve different muscarinic receptor subtypes have been identifIed using molecular biological techniques to date (Bonner et al. 1988) . Future studies utilizing ligands specifIc to each subtype, when they become available, will enhance understanding of changes that occur in the aging brain and in dementia.
